Alnylam grants InterfeRx agent to Quark Biotech
Alnylam Pharmaceuticals says that it has granted fellow USA-based Quark Biotech licenses to InterfeRx to discover, develop, and commercialize RNAi therapeutics targeting the p53 and RTP801 genes for certain diseases. Quark has filed Investigational New Drug applications for RNAi therapeutics for both targets, in the case of p53 for the treatment of renal failure, and of RTP801 for the treatment of ocular diseases, specifically macular degeneration.
Detailed financial terms were not disclosed, but include upfront, annual and milestone payments, as well as royalties on sales of any products covered by the licensing agreements. Simultaneously, Quark has agreed to withdraw its support of opposition to the Kreutzer-Limmer patent series currently granted in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze